Alivus Life Sciences Limited (BOM:543322)
1,052.35
+39.80 (3.93%)
At close: Feb 20, 2025
Alivus Life Sciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2018 |
Net Income | - | 4,709 | 4,670 | 4,187 | 3,516 | 3,131 | Upgrade
|
Depreciation & Amortization | - | 497.78 | 406.48 | 369.2 | 322.9 | 284.85 | Upgrade
|
Other Amortization | - | 36.74 | 14.46 | 9.57 | 11.04 | 8.83 | Upgrade
|
Loss (Gain) From Sale of Assets | - | 10.11 | 5.58 | 7.43 | 5.84 | 12.3 | Upgrade
|
Stock-Based Compensation | - | 43.75 | 31.85 | 34.98 | - | - | Upgrade
|
Provision & Write-off of Bad Debts | - | 31.66 | 3.71 | 48.19 | - | - | Upgrade
|
Other Operating Activities | - | 147.03 | 64.97 | 320.84 | 1,101 | 415.74 | Upgrade
|
Change in Accounts Receivable | - | 378.6 | -1,336 | -592.15 | 81.01 | -1,781 | Upgrade
|
Change in Inventory | - | -826.26 | -972.27 | -28.23 | -1,006 | -119.32 | Upgrade
|
Change in Accounts Payable | - | -341.21 | 907.79 | 737.49 | 340.89 | 193.02 | Upgrade
|
Change in Other Net Operating Assets | - | -551.93 | -735.63 | 881.29 | -491.21 | -195.24 | Upgrade
|
Operating Cash Flow | - | 4,135 | 3,060 | 5,976 | 3,881 | 1,950 | Upgrade
|
Operating Cash Flow Growth | - | 35.13% | -48.79% | 53.97% | 99.03% | 1783.76% | Upgrade
|
Capital Expenditures | - | -1,290 | -1,628 | -1,322 | -679.93 | -511.66 | Upgrade
|
Sale of Property, Plant & Equipment | - | 4.65 | 1.74 | 4.69 | 16.34 | 2.93 | Upgrade
|
Investment in Securities | - | - | 1.11 | 28.05 | -28.05 | - | Upgrade
|
Other Investing Activities | - | 120.21 | 157.66 | 66.7 | 4.3 | 3.55 | Upgrade
|
Investing Cash Flow | - | -1,165 | -1,467 | -1,222 | -687.34 | -505.18 | Upgrade
|
Short-Term Debt Repaid | - | - | - | -9,329 | -2,138 | -1,366 | Upgrade
|
Long-Term Debt Repaid | - | -22.09 | -11.28 | -13.65 | - | - | Upgrade
|
Total Debt Repaid | - | -22.09 | -11.28 | -9,342 | -2,138 | -1,366 | Upgrade
|
Net Debt Issued (Repaid) | - | -22.09 | -11.28 | -9,342 | -2,138 | -1,366 | Upgrade
|
Issuance of Common Stock | - | - | - | 10,119 | - | - | Upgrade
|
Common Dividends Paid | - | -2,757 | -3,859 | -1,287 | - | - | Upgrade
|
Other Financing Activities | - | -15.46 | -5.47 | -277.64 | - | - | Upgrade
|
Financing Cash Flow | - | -2,794 | -3,876 | -787.96 | -2,138 | -1,366 | Upgrade
|
Net Cash Flow | - | 175.91 | -2,283 | 3,966 | 1,056 | 79.37 | Upgrade
|
Free Cash Flow | - | 2,845 | 1,432 | 4,654 | 3,201 | 1,438 | Upgrade
|
Free Cash Flow Growth | - | 98.69% | -69.23% | 45.39% | 122.55% | 13905.94% | Upgrade
|
Free Cash Flow Margin | - | 12.46% | 6.63% | 21.92% | 16.98% | 9.36% | Upgrade
|
Free Cash Flow Per Share | - | 23.19 | 11.69 | 39.60 | 29.69 | 13.34 | Upgrade
|
Cash Interest Paid | - | 15.46 | 5.47 | 277.64 | - | - | Upgrade
|
Cash Income Tax Paid | - | 1,630 | 1,536 | 1,382 | 1,086 | 925.36 | Upgrade
|
Levered Free Cash Flow | - | 2,108 | 553.75 | 3,756 | 1,715 | 432.5 | Upgrade
|
Unlevered Free Cash Flow | - | 2,117 | 557.17 | 3,931 | 2,262 | 641.97 | Upgrade
|
Change in Net Working Capital | - | 1,060 | 2,022 | -1,221 | 902.37 | 1,914 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.